Case report: successful use of antifibrinolytic therapy in acquired factor VIII deficiency.
Acquired factor VIII deficiency is a rare immunologic disorder characterized by severe bleeding due to an antibody inhibitor directed against factor VIII. Treatment of this coagulopathy often is ineffective and costly. The authors report a case of acquired factor VIII deficiency in a patient who developed severe recurrent epistaxis. Antifibrinolytic therapy with epsilon aminocaproic acid (EACA) was used to control the epistaxis with excellent results. To the authors' knowledge, this is the first report of the efficacy of EACA therapy in acquired factor VIII deficiency. Use of antifibrinolytic therapy may represent a relatively safe, effective, and inexpensive approach to treating factor VIII inhibitors.
Lalwani
R B
RB
Department of Medicine, California Pacific Medical Center, San Francisco 94118.
Stricker
R B
RB
D000368:Aged; D015119:Aminocaproic Acid / Q000191:economics / Q000627:therapeutic use*; D004844:Epistaxis / Q000209:etiology; D005169:Factor VIII / Q000276:immunology; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy* / Q000191:economics / Q000276:immunology; D006801:Humans; D008297:Male
D005169:Factor VIII; D015119:Aminocaproic Acid